28466-21-9

Basic information

• Product Name: 4-AMINO-1,3,5-TRIMETHYLPYRAZOLE
• Synonyms: TIMTEC-BB SBB006986;AKOS PAO-0230;AKOS B000505;4-AMINO-1,3,5-TRIMETHYLPYRAZOLE;1,3,5-TRIMETHYL-1H-PYRAZOL-4-AMINE;1,3,5-TRIMETHYL-1H-PYRAZOL-4-YLAMINE;BUTTPARK 29\06-78;ART-CHEM-BB B000505
• CAS NO: 28466-21-9
• Molecular Formula: C₆H₁₁N₃
• Molecular Weight: 125.17
• EINECS: -0
• Mol File: 28466-21-9.mol
• Article Data: 10

Chemical Properties

• Melting Point: 96 °C
• Boiling Point: 236℃
• Flash Point: 97℃
• Appearance: brown solid
• Density: 1.13
• Vapor Pressure: 0.048mmHg at 25°C
• Refractive Index: 1.568
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 4.75±0.10(Predicted)
• BRN: 110739
• CAS DataBase Reference: 4-AMINO-1,3,5-TRIMETHYLPYRAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-AMINO-1,3,5-TRIMETHYLPYRAZOLE(28466-21-9)
• EPA Substance Registry System: 4-AMINO-1,3,5-TRIMETHYLPYRAZOLE(28466-21-9)

Safety Data

• Hazard Codes: Xi
• Safety Statements: S22:Do not inhale dust.; S24/25:Avoid contact with skin and eyes.
• RTECS: UQ6125100
• Hazardous Substances Data: 28466-21-9(Hazardous Substances Data)

Usage

General Description

4-AMINO-1,3,5-TRIMETHYLPYRAZOLE is a chemical compound with the molecular formula C6H10N4. It is a pyrazole derivative that is commonly used as a building block in the synthesis of pharmaceuticals and agrochemicals. 4-AMINO-1,3,5-TRIMETHYLPYRAZOLE is classified as an amino compound, meaning it contains an amine group (-NH2) and is also substituted with three methyl groups. 4-AMINO-1,3,5-TRIMETHYLPYRAZOLE is known for its high stability and reactivity, making it a valuable intermediate in the production of various active ingredients for different applications. Additionally, it has been studied for its potential use in the development of new materials and chemical processes.

InChI:InChI=1/C6H11N3/c1-4-6(7)5(2)9(3)8-4/h7H2,1-3H3

Upstream product

• 1125-30-0 1,3,5-trimethyl-4-nitro-1H-pyrazole 
• 67-51-6 3,5-dimethyl-1H-pyrazole 
• 15801-69-1 4-bromo-1,3,5-trimethylpyrazole 
• 14531-55-6 3,5-dimethyl-4-nitro-1H-pyrazole 
• 1123-49-5 3,5-dimethyl-4-nitroisoxazole 
• 29917-12-2 Isonitrosoacetylacetone 
• 7171-70-2 1,3,5-trimethyl-4-nitrosopyrazole 

Downstream Products

• 63204-11-5 4-isothiocyanato-1,3,5-trimethyl-1H-pyrazole 
• 1215008-91-5 4-(2-methylthiazol-4-yl)-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide 
• 1215011-19-0 6-(3-(4-benzylpiperazin-1-yl)pyrrolidin-1-yl)-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridine-3-sulfonamide 
• 1352127-11-7 4-bromo-N-isobutyl-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzamide 
• 1215013-78-7 2,6-dichloro-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide 
• 1215009-51-0 3',5'-dichloro-4'-(N-(1,3,5-trimethyl-1H-pyrazol-4-yl)sulfamoyl)-[1,1'-biphenyl]-3-carboxamide 
• 1215009-18-9 6-(benzylamino)-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridine-3-sulfonamide 
• 1215010-33-5 6-((4-((dimethylamino)methyl)benzyl)(methyl)amino)-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridine-3-sulfonamide 
• 1215010-77-7 6-((2-(4-phenylpiperazin-1-yl)ethyl)amino)-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridine-3-sulfonamide 
• 1215010-99-3 6-((2-(4-benzylpiperazin-1-yl)ethyl)amino)-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridine-3-sulfonamide 
• 1215009-50-9 2,6-dichloro-4-(isoquinolin-5-yl)-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide 
• 1215010-53-9 3,5-dichloro-4'-((4-methylpiperazin-1-yl)methyl)-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)-[1,1'-biphenyl]-4-sulfonamide 
• 1215010-48-2 3,5-dichloro-4'-((diethylamino)methyl)-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)-[1,1'-biphenyl]-4-sulfonamide 
• 1215010-54-0 2,6-dichloro-4-(6-(piperazin-1-yl)pyridin-3-yl)-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide 

Relevant articles and documents

BICYCLIC KINASE INHIBITORS AND USES THEREOF

The invention relates to kinase inhibitors, in particular inhibitors of protein kinases including the SIK-family, CSF1R, HCK, TEK-family, BRK, ABL, KIT and/or their mutants. Although structurally similar to other bicyclic kinase inhibitors, the kinase inhibitors of the invention are distinctive; possessing a particular class of heterocyclic moiety. Such kinase inhibitors can display one or more certain properties distinct to their structurally similar kinase inhibitors. The kinase inhibitors of the invention or pharmaceutical compositions comprising them may be used in the treatment of a disorder or condition, such as a proliferative disorder, for example, a leukaemia or solid tumour. In particular, these and other structurally related kinase inhibitors may be used in the treatment of a proliferative disorder - such as a mixed phenotype acute leukaemia (MPAL) - characterised by (inter-alia) the presence of MEF2C protein, a human chromosomal translocation at 11q23, and/or a KMT2A fusion oncoprotein. The kinase inhibitors or pharmaceutical compositions of the invention may be used topically to modulate skin pigmentation in a subject, for example to impart UV protection and reduce skin cancer risk.

Depsipeptides Featuring a Neutral P1 Are Potent Inhibitors of Kallikrein-Related Peptidase 6 with On-Target Cellular Activity

Kallikrein-related peptidase 6 (KLK6) is a secreted serine protease that belongs to the family of tissue kallikreins (KLKs). Many KLKs are investigated as potential biomarkers for cancer as well as therapeutic drug targets for a number of pathologies. KLK6, in particular, has been implicated in neurodegenerative diseases and cancer, but target validation has been hampered by a lack of selective inhibitors. This work introduces a class of depsipeptidic KLK6 inhibitors, discovered via high-throughput screening, which were found to function as substrate mimics that transiently acylate the catalytic serine of KLK6. Detailed structure-activity relationship studies, aided by in silico modeling, uncovered strict structural requirements for potency, stability, and acyl-enzyme complex half-life. An optimized scaffold, DKFZ-251, demonstrated good selectivity for KLK6 compared to other KLKs, and on-target activity in a cellular assay. Moreover, DKFZ-633, an inhibitor-derived activity-based probe, could be used to pull down active endogenous KLK6.

COMPOUNDS

The present invention relates to novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, to compositions containing them and to their use in the treatment of or prevention of diseases characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).